Abstract
The potent novel poly(ADP-ribose) polymerase (PARP) inhibitor, NU1025, enhances the cytotoxicity of DNA-methylating agents and ionizing radiation by inhibiting DNA repair. We report here an investigation of the role of PARP in the cellular responses to inhibitors of topoisomerase I and II using NU1025. The cytotoxicity of the topoisomerase I inhibitor, camptothecin, was increased 2.6-fold in L1210 cells by co-incubation with NU1025. Camptothecin-induced DNA strand breaks were also increased 2.5-fold by NU1025 and exposure to camptothecin-activated PARP. In contrast, NU1025 did not increase the DNA strand breakage or cytotoxicity caused by the topoisomerase II inhibitor etoposide. Exposure to etoposide did not activate PARP even at concentrations that caused significant levels of apoptosis. Taken together, these data suggest that potentiation of camptothecin cytotoxicity by NU1025 is a direct result of increased DNA strand breakage, and that activation of PARP by camptothecin-induced DNA damage contributes to its repair and consequently cell survival. However, in L1210 cells at least, it would appear that PARP is not involved in the cellular response to etoposide-mediated DNA damage. On the basis of these data, PARP inhibitors may be potentially useful in combination with topoisomerase I inhibitor anticancer chemotherapy. © 2001 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Banasik M, Komura H, Shimoyama M and Ueda K (1992) Specific inhibitors of poly(ADP-ribose)synthetase and mono(ADP-ribosyl)transferase. J Biol Chem 267: 1569–1575
Barrows LR, Holden JA, Anderson M and D'Arpa P (1998) The CHO XRCC1 mutant, EM9, deficient in DNA ligase III activity, exhibits hypersensitivity to camptothecin-independent of DNA replication. Mutat Res 408: 103–110
Benjamin RC and Gill DM (1980) Poly(ADP-ribose) synthesis in vitro programmed by damaged DNA: comparison of DNA molecules containing different types of strand breaks. J Biol Chem 255: 10502–10508
Bernardi R, Negri C, Donzelli M, Torti M, Prosperi E and Scovassi AI (1995) Activation of poly(ADP-ribose) polymerase in apoptotic human cells. Biochimie 77: 378–384
Bernges F and Zeller WJ (1996) Combination effects of poly(ADP-ribose) polymerase inhibitors and DNA-damaging agents in ovarian tumour cell lines – with special reference to cisplatin. J Cancer Res Clin Oncol 122: 665–670
Boulton S, Pemberton LC, Porteous JK, Curtin NJ, Griffin RJ, Golding BT and Durkacz BW (1995) Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of pol(ADP-ribose)polymerase inhibitors. Br J Cancer 72: 849–856
Bowman KJ, Curtin NJ, Golding BT, Griffin RJ and White A (1998) Potentiation of anticancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors, NU1025 and NU1064. Br J Cancer 78: 1269–1277
Caldecott K and Jeggo P (1991) Cross-sensitivity of γ-ray-sensitive hamster mutants to cross-linking agents. Mutat Res DNA Repair 255: 111–121
Caldecott KW, Aofouchi S, Johnson P and Shall S (1996) XRCC1 polypeptide interacts with DNA polymerase beta and possibly poly(ADP-ribose) polymerase, and DNA ligaseIII is a novel molecular nick-sensor in vitro. Nucleic Acids Res 24: 4387–4394
Chatterjee S, Cheng M-F, Trivedi D, Petzold SJ and Berger NA (1990) Camptothecin hypersensitivity in poly(adenine diphosphate-ribose) polymerase-deficient cell lines. Cancer Commun 1: 401–407
Chatterjee S, Cheng M-F, Berger SJ and Berger NA (1994) Induction of M r 78,00 glucose-related stress protein in poly(adenosine diphosphate-ribose) polymerase-and nicotinamide adenine dinucleotide-deficient V70 cell lines and its relation to resistance to the topoisomerase II inhibitor etoposide. Cancer Res 54: 4405–4411
Dantzer F, Schreiber V, Niedergang C, Trucco C, Flatter E, de la Rubia G, Oliver J, Rolli V, Menissier-de Murcia J and de Murcia G (1999) Involvement of poly(ADP-ribose) polymerase in base excision repair. Biochimie 81: 69–75
Darby MK, Schmitt B, Jongstra-Bilen J and Vosberg HP (1985) Inhibition of calf thymus type II topoisomerase by poly (ADP-ribosylation). EMBO J 4: 2129–2134
Daugherty JP, Simpson TA, Jr. and Mullins DW, Jr. (1988) Effect of hyperthermia and doxorubicin on nucleoid sedimentation and poly(ADP-ribose)polymerase activity in L1210 cells. Cancer Chemother Pharmacol 21: 229–232
Delaney CA, Wang L-Z, Kyle S, Srinivasan S, White AW, Calvert AH, Curtin NJ, Durkacz BW, Hostomsky Z, Maegley K, Golding BT, Griffin RG and Newell DR (2000) Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(ADP-ribose) polymerase inhibitors in a panel of human tumour cell lines. Clin Cancer Res 6: 2860–2867
de Murcia G and Menissier-de Murcia J (1994) Poly(ADP-ribose)polymerase: a molecular nick-sensor. TIBS 19: 172–176
Eriksson C, Busk L and Brittebo EB (1996) 3-Aminobenzamide: effects on cytochrome P450-dependent metabolism of chemicals and on the toxicity of dichlobenil in the olfactory mucosa. Toxicol Appl Pharmacol 136: 324
Ferro AM and Olivera BM (1984) Poly (ADP-ribosylation) of DNA topoisomerase I from calf thymus, J Biol Chem 259: 547–554
Griffin RJ, Curtin NJ, Newell DR, Golding BT, Durkacz BW and Calvert AH (1995 a) The role of inhibitors of poly(ADP-ribose)polymerase as resistance modifying agents in cancer therapy. Biochimie 77: 364–367
Griffin RJ, Pemberton LC, Rhodes D, Bleasdale C, Bowman K, Calvert AH, Curtin NJ, Durkacz BW, Newell DR, Porteous JK and Golding BT (1995 b) Novel potent inhibitors of the DNA repair enzyme poly(ADP-ribose)polymerase (PARP). Anti-Cancer Drug Design 10: 507–514
Griffin RJ, Srinivasan S, White AW, Bowman K, Calvert AH, Curtin NJ, Newell DR and Golding BT (1996) Novel benzimidazole and quinazolinone inhibitors of the DNA repair enzyme, poly (ADP-ribose)polymerase. Pharmaceut Sci 2: 43–47
Halldorsson H, Gray DA and Shall S (1978) Poly(ADP-ribose)polymerase activity in nucleotide permeable cells. FEBS Lett 85: 349–352
Jeggo PA, Caldecott K, Pidsley S and Banks GR (1989) Sensitivity of Chinese hamster ovary mutants defective in DNA double strand break repair to topoisomerase II inhibitors. Cancer Res 49: 7057–7063
Kaufmann SH (1998) Cell death induced by topoisomerase-targeted drugs: more questions than answers. Biochim Biophys Acta 1400: 185–211
Kaufmann SH, Charron M, Burke PJ and Karp JE (1995) Changes in topoisomerase I levels and localisation during myeloid maturation in vitro and in vivo. Cancer Res 55: 1255–1260
Kohn KW, Ewig RA, Erickson LC and Zwelling LA (1981) Measurement of strand breaks and cross-links by alkaline elution. DNA repair: a laboratory manual of research procedures, Friberg EC, Hanawalt PC (eds) pp. 379–401, Marcel Dekker Inc.: New York
Kubota M, Tanizawa A, Hashimoto H, Shimizu T, Takimoto T, Kitoh T, Akiyama Y and Mikawa H (1990) Cell type dependent activation of poly(ADP-ribose) synthesis following treatment with etoposide. Leukaemia Res 14: 371–375
Marks DI and Fox RM (1991) DNA damage, poly(ADP-ribosyl)ation and apoptotic cell death as a potential common pathway of cytotoxic drug action. Biochem Pharmacol 42: 1859–1867
Mason M, Niedergang C, Schreiber V, Muller S, Menissier deMurcia J and deMurcia G (1998) XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol Cell Biol 18: 3563
Mattern MR, Mong S-M, Bartus HF, Mirabelli CK, Crooke ST and Johnson RK (1987) Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells. Cancer Res 47: 1793–1798
Milam KM, Thomas GH and Cleaver JE (1986) Disturbances in DNA precursor metabolism associated with exposure to an inhibitor of poly(ADP-ribose) synthetase. Exp Cell Res 165: 260
Moses K, Harris AL and Durkacz BW (1988 a) Adenosine-diphosphoribosyl transferase inhibitors can protect against or potentiate the cytotoxicity of S-phase acting drugs. Biochem Pharmacol 37: 2155
Moses K, Harris AL and Durkacz BW (1988 b) Synergistic enhancement of 6-thioguanine by ADP-ribosyltransferase inhibitors. Cancer Res 48: 5650
Moses K, Willmore E, Harris AL and Durkacz BW (1990) Correlation of enhanced 6-mercaptopurine cytotoxicity with increased phosphoribosylpyrophosphate levels in Chinese hamster ovary cells treated with 3-aminobenzamide. Cancer Res 50: 1992
Negri C, Bernardi R, Braghetti A, Astaldi Ricotti GCB and Scovassi IA (1993) The effect of the chemotherapeutic drug VP-16 on poly(ADP-ribosylation) in apoptotic HeLa cells. Carcinogenesis 14: 2559–2564
Pommier YM, Leteurtre F, Fesen MR, Fujimori A, Bertrand R, Solary E, Kohlhagen G and Kohn KW (1994) Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest 12: 530–542
Strumberg D, Pilon AA, Smith M, Malkas LH and Pommier Y (1999) Selective inhibition of lagging strand DNA replication by camptothecin-induced topoisomerase I-poisoning. Proc Am Assoc Cancer Res 40: 208
Suto MJ, Turner WR, Arundel-Suto CM, Werbel LM and Sebolt-Leopold JS (1991) Dihydroisoquinolinones: the design and synthesis of a new series of potent inhibitors of poly(ADP-ribose)polymerase. Anti-Cancer Drug Design 7: 107–117
Tanizawa A, Kubota M, Hashimoto H, Shimizu T, Takimoto T, Kitoh T, Akiyama Y and Mikawa H (1989) VP-16-induced nucleotide pool changes and poly (ADP-ribose) synthesis: the role of VP-16 in interphase death. Exp Cell Res 185: 237–246
Yang S-W, Burgin AB, Huizenga BN, Robertson CA, Yao KC and Nash HA (1996) A eukaryotic enzyme that can disjoin dead-end covalent complexes between DNA and type 1 topoisomerases. Proc Natl Acad Sci USA 93: 11534–11539
Zwelling LA, Kerrigan D, Pommier Y, Michaels S, Steren A and Kohn KW (1982) Formation and resealing of intercalator-induced DNA strand breaks in permeabilised L1210 cells without the stimulated synthesis of poly (ADP-ribose). J Biol Chem 257: 8957–8963
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Bowman, K., Newell, D., Calvert, A. et al. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. Br J Cancer 84, 106–112 (2001). https://doi.org/10.1054/bjoc.2000.1555
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1555